Form 4: Harmony Biosciences CFO Kapadia Reports Equity Grants

Harmony Biosciences' Chief Financial Officer, Sandip Kapadia, reported new equity grants and the vesting of previously awarded restricted stock units, along with shares withheld for tax obligations.

Summary

• Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported several equity transactions.
• On January 22, 2026, Kapadia was granted 42,600 stock options with an exercise price of $36.76, vesting 25% on January 22, 2027, and quarterly thereafter for four years.
• Also on January 22, 2026, Kapadia received a grant of 12,200 Restricted Stock Units (RSUs), vesting in four equal annual installments starting January 22, 2027.
• On January 24, 2026, 3,813 shares of common stock vested from a previously granted RSU award (January 24, 2024).
• On January 25, 2026, 4,725 shares of common stock vested from another previously granted RSU award (January 25, 2025).
• To satisfy income tax withholdings related to the RSU vestings, 2,239 shares were disposed of on January 24, 2026, and 2,553 shares on January 25, 2026, both at a price of $36.82 per share.
• Following these transactions, Kapadia beneficially owns 42,600 stock options, 12,200 newly granted RSUs, 7,625 remaining unvested RSUs from the 2024 grant, and 14,175 remaining unvested RSUs from the 2025 grant.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation, including new equity grants and vesting of prior awards, which is generally positive for management retention and alignment. The disposition of shares for tax purposes is a standard, neutral event. No negative operational or financial news is present.

Positives

• Grant of 42,600 stock options to the CFO, aligning management incentives with shareholder value.
• Grant of 12,200 restricted stock units (RSUs) to the CFO, further aligning long-term interests.
• Vesting of 8,538 shares (3,813 + 4,725) from prior RSU awards, indicating continued compensation and retention of the CFO.

Negatives

• Disposal of 4,792 shares (2,239 + 2,553) to cover tax obligations, which reduces the direct shareholding from vested units.

Future Outlook

The filing details future vesting schedules for newly granted stock options and restricted stock units, indicating a long-term incentive structure for the Chief Financial Officer. The stock options will vest over four years starting January 22, 2027, and expire on January 22, 2036. The new restricted stock units will also vest in four equal annual installments beginning January 22, 2027. This suggests a continued commitment to retaining key management through equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, specifically related to executive compensation. It reflects standard practices in the biotechnology and pharmaceutical industry where equity grants, such as stock options and restricted stock units, are common tools for attracting, retaining, and incentivizing key executives. The vesting schedules are typical for long-term incentive plans, aligning executive performance with shareholder value over several years.

Comparison to Industry Standards

• The use of stock options and restricted stock units (RSUs) for executive compensation is a standard practice across the biotechnology and pharmaceutical industry, comparable to compensation structures at companies like Biogen, Gilead Sciences, or Amgen.
• The four-year vesting schedule for both stock options and RSUs is a common industry benchmark for long-term incentive plans, designed to promote executive retention and align interests with long-term company performance.
• The practice of withholding shares to cover tax obligations upon RSU vesting is also a standard, efficient mechanism for managing executive compensation taxes, widely adopted by publicly traded companies.

Related Party Transactions

• The transactions involve equity compensation for a corporate officer, which is a standard related-party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grants of stock options and RSUs align the CFO's long-term interests with shareholder value creation. The vesting and subsequent tax-related share dispositions are routine and reflect the ongoing cost of executive compensation.
• Employees: This filing primarily concerns executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• The stock options will begin vesting on January 22, 2027, with subsequent quarterly vesting until January 22, 2030.
• The newly granted restricted stock units will begin vesting in four equal annual installments starting January 22, 2027.
• Further vesting events for the remaining unvested restricted stock units from the 2024 and 2025 grants will occur on their respective schedules.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including new equity grants and the vesting of previously awarded units. Such disclosures are standard and generally do not provide new information that would significantly alter the investment thesis for Harmony Biosciences. The transactions reflect ongoing management incentives and retention, which are neutral to slightly positive, but do not warrant a change in an existing investment position. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial news.

Keywords

Harmony Biosciences Holdings Inc, HRMY, Sandip Kapadia, CFO, Form 4, SEC filing, insider trading, stock options, restricted stock units, RSU vesting, equity compensation, beneficial ownership